Novartis AG
Use of a H3R inverse agonist for the treatment of shift work disorder
Last updated:
Abstract:
The invention relates to the use of a H3R inverse agonist for the treatment of shift work disorder.
Status:
Grant
Type:
Utility
Filling date:
17 Apr 2018
Issue date:
28 Jun 2022